ErbB receptor tyrosine kinase/NF-κB signaling controls mammosphere formation in human breast cancer

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 17, 2012, Pages 6584-6589

  Hinohara, Kunihiko ^a   Kobayashi, Seiichiro ^a   Kanauchi, Hajime ^b   Shimizu, Seiichiro ^b   Nishioka, Kotoe ^c   Tsuji, Ei Ichi ^c   Tada, Kei Ichiro ^c   Umezawa, Kazuo ^d   Mori, Masaki ^e   Ogawa, Toshihisa ^c   Inoue, Jun Ichiro ^a   Tojo, Arinobu ^a   Gotoh, Noriko ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b Showa General Hospital   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d KEIO UNIVERSITY   (Japan)

^e OSAKA UNIVERSITY   (Japan)

Author keywords

Cancer stem cells; EGF; HER; Inflammation; Tumor sphere

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; I KAPPA B ALPHA SUPER REPRESSOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; MESSENGER RNA; NEU DIFFERENTIATION FACTOR; NUCLEIC ACID BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CANCER STEM CELL; CARCINOGENESIS; CELL POPULATION; CELL RENEWAL; CELL STRAIN MCF 7; ENZYME ACTIVATION; ENZYME INDUCTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MAMMOSPHERE FORMATION; MOLECULAR DYNAMICS; MOUSE; MULTICELLULAR SPHEROID; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; INTERLEUKIN-8; MICE; MICE, INBRED NOD; MICE, SCID; NEUREGULIN-1; NF-KAPPA B; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-2; RNA, MESSENGER; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84860163816     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1113271109     Document Type: Article

References (41)

1. Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414:105-111. (Pubitemid 33041634)
2. Gotoh N (2011) Potential signaling pathways activated in cancer stem cells in breast cancer. Cancer Stem Cells Theories and Practice, ed Shostak S (InTech, Vienna, Austria), p 6.
3. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983-3988. (Pubitemid 36418143)
4. Boiko AD, et al. (2010) Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature 466:133-137.
5. Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3:730-737. (Pubitemid 27298715)
6. Chan KS, et al. (2009) Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci USA 106:14016-14021.
7. Dalerba P, et al. (2007) Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 104:10158-10163. (Pubitemid 47175279)
8. O'Brien CA, Pollett A, Gallinger S, Dick JE (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445:106-110. (Pubitemid 46067310)
9. Prince ME, et al. (2007) Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 104: 973-978. (Pubitemid 46154721)
10. Singh SK, et al. (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63:5821-5828. (Pubitemid 37187480)
11. Cordenonsi M, et al. (2011) The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell 147:759-772.
12. Pece S, et al. (2010) Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 140:62-73.
13. Dontu G, et al. (2003) In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 17:1253-1270. (Pubitemid 36583168)
14. Ponti D, et al. (2005) Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 65:5506-5511. (Pubitemid 40911148)
15. Yu F, et al. (2007) let-7 Regulates self renewal and tumorigenicity of breast cancer cells. Cell 131:1109-1123. (Pubitemid 350235025)
16. Scheel C, et al. (2011) Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell 145:926-940.
17. Hsing CH, et al. (2011) Anesthetic propofol reduces endotoxic inflammation by inhibiting reactive oxygen species-regulated Akt/IKKβ/NF-κB signaling. PLoS ONE 6: e17598.
18. Hinohara K, Gotoh N (2010) Inflammatory signaling pathways in self-renewing breast cancer stem cells. Curr Opin Pharmacol 10:650-654.
19. Murohashi M, et al. (2010) Gene set enrichment analysis provides insight into novel signalling pathways in breast cancer stem cells. Br J Cancer 102:206-212.
20. Hayes NV, Gullick WJ (2008) The neuregulin family of genes and their multiple splice variants in breast cancer. J Mammary Gland Biol Neoplasia 13:205-214.
21. Krane IM, Leder P (1996) NDF/heregulin induces persistence of terminal end buds and adenocarcinomas in the mammary glands of transgenic mice. Oncogene 12: 1781-1788. (Pubitemid 26146303)
22. Atlas E, et al. (2003) Heregulin is sufficient for the promotion of tumorigenicity and metastasis of breast cancer cells in vivo. Mol Cancer Res 1:165-175. (Pubitemid 36330198)
23. Menendez JA, Mehmi I, Lupu R (2006) Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression. J Clin Oncol 24:3735-3746. (Pubitemid 46622312)
24. Dunn M, et al. (2004) Co-expression of neuregulins 1, 2, 3 and 4 in human breast cancer. J Pathol 203:672-680. (Pubitemid 38714104)
25. Korkaya H, Paulson A, Iovino F, Wicha MS (2008) HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 27: 6120-6130.
26. Ginestier C, et al. (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1:555-567. (Pubitemid 350056407)
27. Mani SA, et al. (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133:704-715. (Pubitemid 351636299)
28. Nishimura D, et al. (2006) DHMEQ, a novel NF-kappaB inhibitor, induces apoptosis and cell-cycle arrest in human hepatoma cells. Int J Oncol 29:713-719.
29. Charafe-Jauffret E, et al. (2009) Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 69: 1302-1313.
30. Ginestier C, et al. (2010) CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest 120:485-497.
31. Pahl HL (1999) Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18:6853-6866.
32. Diehn M, et al. (2009) Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458:780-783.
33. Gupta PB, et al. (2009) Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138:645-659.
34. Morrison BJ, Schmidt CW, Lakhani SR, Reynolds BA, Lopez JA (2008) Breast cancer stem cells: Implications for therapy of breast cancer. Breast Cancer Res 10:210.
35. Stove C, Bracke M (2004) Roles for neuregulins in human cancer. Clin Exp Metastasis 21:665-684. (Pubitemid 40755007)
36. Liu S, Wicha MS (2010) Targeting breast cancer stem cells. J Clin Oncol 28:4006-4012.
37. Karin M, Greten FR (2005) NF-kappaB: Linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5:749-759. (Pubitemid 41400849)
38. Hynes NE, Lane HA (2005) ERBB receptors and cancer: The complexity of targeted inhibitors. Nat Rev Cancer 5:341-354. (Pubitemid 40637826)
39. Olayioye MA, Neve RM, Lane HA, Hynes NE (2000) The ErbB signaling network: Receptor heterodimerization in development and cancer. EMBO J 19:3159-3167. (Pubitemid 30428195)
40. Vogel CL, et al. (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726. (Pubitemid 34111379)
41. Lim E, et al.; kConFab (2009) Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 15: 907-913.